Novel oral anticoagulants

Abstract

Get full access to this article

View all access options for this article.

References

BNF. (2013). British national formulary. London: The Pharmaceutical Press..

Connolly

S. J.

Ezekowitz

M. D.

Yusuf

Eikelboom

Oldgren

Parekh

…, Wallentin

(2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 361: 1139–1151. doi: 10.1056/NEJMoa0905561.

HPSU. (2012). Summary of potential advantages of warfarin, dabigatran and rivaroxaban for stroke prevention in AF. Retrieved from www.sechealthpolicysupportunit.nhs.uk.

NICE. (2012). Final appraisal determination - Rivaroxaban for the treatment of deep vein thrombosis and prevention of deep vein thrombosis and pulmonary embolism. Retrieved from www.nice.org.uk/nicemedia/live/13332/59383/59383.pdf.

Patel

M. R.

Mahaffey

K. W.

Garg

Pan

Singer

D. E.

Hacke

…, Califf

R. M.

(2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 365: 883–891. doi: 10.1056/NEJMoa1009638.

Scottish Intercollegiate Guidelines Network. (2012). SIGN 129, Antithrombotics: indications and management. Retrieved from www.sign.ac.uk/pdf/SIGN129.pdf.

Van de Werf

Brueckmann

Connolly

S. J.

Friedman

Granger

C. B.

Härtter

…, Eikelboom

J. W.

(2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal 163: 931–937.e1. doi: 10.1016/j.ahj.2012.03.011.